Prognostic biomarkers in malignant lymphomas

Leukemia and Lymphoma

Volumn 51, Issue SUPPL. 1, 2010, Pages 11-19

  Gascoyne, Randy D ^a   Rosenwald, Andreas ^b   Poppema, Sibrand ^c   Lenz, Georg ^d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

biomarkers; diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; microenvironment; prognosis

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CHEMOKINE; CHEMOKINE RECEPTOR CCR4; CISPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CXCL9 CHEMOKINE; CYCLIN B1; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EOTAXIN; ETOPOSIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON REGULATORY FACTOR 4; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; RANTES; RITUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME LOSS; CLINICAL RESEARCH; DENDRITIC CELL; FOLLICULAR LYMPHOMA; GENE MUTATION; GENE REARRANGEMENT; GENETIC MARKER; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MICROVASCULATURE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT;

GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956427574     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.500046     Document Type: Review

References (56)

1. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008;168:469-476.
2. A predictive model for aggressive non-Hodgkins lymphoma. The international non-Hodgkins lymphoma prognostic factors project. N Engl J Med 1993;329:987-994.
3. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6351-6357.
4. Hartmann EM, Ott G, Rosenwald A. Molecular biology and genetics of lymphomas. Hematol Oncol Clin North Am 2008;22:807-823, vii.
5. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348: 334-336.
6. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007.
7. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkins lymphoma. Groupe dEtude des Lymphomes de lAdulte (GELA). Blood 1996;87:265-272.
8. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkins lymphoma: an analysis of 83 cases. J Clin Oncol 1994;12:149-154.
9. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-3537.
10. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003;101:1220-1235.
11. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006;13:1027-1036.
12. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-799.
13. Young KH, Leroy K, Moller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088-3098.
14. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-346.
15. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
16. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
17. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
18. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005;87:163-208.
19. Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, Salles G. Biomarkers and prognosis in malignant lymphomas. Clin Lymphoma Myeloma 2009;9:160-166.
20. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-3433.
21. Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003;101:2363-2367.
22. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
23. Montes-Moreno S, Roncador G, Maestre L, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood 2008;111:351-358.
24. Lossos IS, Alizadeh AA, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 2003;101:433-440.
25. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007;109:1636-1642.
26. Pan Z, Shen Y, Du C, et al. Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells. Am J Pathol 2003;163:135-144.
27. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.
28. Copie-Bergman C, Gaulard P, Leroy K, et al. Immunofluorescence in situ hybridization index predicts survival in patients with diffuse large B-Cell lymphoma treated with R-CHOP: A GELA Study. J Clin Oncol 2009;27:5573-5579.
29. de Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009;62:128-138.
30. Johnson NA, Gascoyne RD. Gene expression signatures in follicular lymphoma: are they ready for the clinic? Haematologica 2008;93:982-987.
31. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104: 1258-1265.
32. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562.
33. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358-6363.
34. Hoglund M, Sehn L, Connors JM, et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 2004;39:195-204.
35. Cheung KJ, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 2009;113:137-148.
36. OShea D, ORiain C, Gupta M, et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009;113:2298-2301.
37. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells. N Engl J Med 2004;351:2159-2169.
38. Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007;110:4455-4463.
39. Cerhan JR, Wang S, Maurer MJ, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007;109:5439-5446.
40. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-2174.
41. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-446.
42. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide- doxorubicinvincristine-prednisone. Clin Cancer Res 2007;13:5784-5789.
43. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423.
44. Swerdlow SH, Campo E, Harris NL. Jaffe ESPSASHTJVJW. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp 1-439.
45. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297.
46. Poppema S, van den BA. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000;10:345-350.
47. Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008;111:2339-2346.
48. Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008;49:1668-1680.
49. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-127.
50. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkins lymphoma. Am J Pathol 1999;154:1685-1691.
51. Beck A, Pazolt D, Grabenbauer GG, et al. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkins disease. J Pathol 2001;194:145-151.
52. Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66: 5716-5722.
53. Ohshima K, Tutiya T, Yamaguchi T, et al. Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells. Int J Cancer 2002;98:567-572.
54. Niens M, Visser L, Nolte IM, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008;140:527-536.
55. Ma Y, Visser L, Blokzijl T, et al. The CD4CD26- T cell population in classical Hodgkin lymphoma displays a distinctive regulatory T cell profile. Lab Invest 2008;88:482-490.
56. Maggio E, van den BA, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkins lymphoma cell lines and tissues. Ann Oncol 2002;13(Suppl 1):52-56.